Pulmonx Research Development from 2010 to 2026

LUNG Stock  USD 1.73  0.03  1.70%   
Pulmonx Corp's Research Development is increasing over the last several years with slightly volatile swings. Research Development is estimated to finish at about 21.2 M this year. During the period from 2010 to 2026 Pulmonx Corp Research Development regressed destribution of quarterly values had coefficient of variationof  100.15 and r-value of  0.94. View All Fundamentals
 
Research Development  
First Reported
2016-12-31
Previous Quarter
5.3 M
Current Value
4.8 M
Quarterly Volatility
1.7 M
 
Covid
 
Interest Hikes
Check Pulmonx Corp financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Pulmonx Corp's main balance sheet or income statement drivers, such as Interest Expense of 4.2 M, Selling General Administrative of 113.8 M or Total Revenue of 101.2 M, as well as many indicators such as Price To Sales Ratio of 3.46, Dividend Yield of 0.0 or PTB Ratio of 1.58. Pulmonx financial statements analysis is a perfect complement when working with Pulmonx Corp Valuation or Volatility modules.
  
Build AI portfolio with Pulmonx Stock
Check out the analysis of Pulmonx Corp Correlation against competitors.
For more detail on how to invest in Pulmonx Stock please use our How to Invest in Pulmonx Corp guide.

Latest Pulmonx Corp's Research Development Growth Pattern

Below is the plot of the Research Development of Pulmonx Corp over the last few years. It is Pulmonx Corp's Research Development historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Pulmonx Corp's overall financial position and show how it may be relating to other accounts over time.
Research Development10 Years Trend
Slightly volatile
   Research Development   
       Timeline  

Pulmonx Research Development Regression Statistics

Arithmetic Mean7,878,575
Geometric Mean3,733,768
Coefficient Of Variation100.15
Mean Deviation6,854,097
Median6,049,000
Standard Deviation7,890,650
Sample Variance62.3T
Range20.6M
R-Value0.94
Mean Square Error8T
R-Squared0.88
Slope1,464,977
Total Sum of Squares996.2T

Pulmonx Research Development History

202621.2 M
202520.2 M
202417.6 M
202318.1 M
202215.4 M
202113.1 M
20207.5 M

About Pulmonx Corp Financial Statements

Pulmonx Corp stakeholders use historical fundamental indicators, such as Pulmonx Corp's Research Development, to determine how well the company is positioned to perform in the future. Although Pulmonx Corp investors may analyze each financial statement separately, they are all interrelated. For example, changes in Pulmonx Corp's assets and liabilities are reflected in the revenues and expenses on Pulmonx Corp's income statement, which ultimately affect the company's gains or losses. Understanding these patterns can help in making the right long-term investment decisions in Pulmonx Corp. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
Research Development20.2 M21.2 M

Currently Active Assets on Macroaxis

When determining whether Pulmonx Corp is a strong investment it is important to analyze Pulmonx Corp's competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Pulmonx Corp's future performance. For an informed investment choice regarding Pulmonx Stock, refer to the following important reports:
Check out the analysis of Pulmonx Corp Correlation against competitors.
For more detail on how to invest in Pulmonx Stock please use our How to Invest in Pulmonx Corp guide.
You can also try the Insider Screener module to find insiders across different sectors to evaluate their impact on performance.
Can Health Care Equipment & Supplies industry sustain growth momentum? Does Pulmonx have expansion opportunities? Factors like these will boost the valuation of Pulmonx Corp. Expected growth trajectory for Pulmonx significantly influences the price investors are willing to assign. Determining accurate worth demands scrutiny of both present operating results and projected expansion capacity. Evaluating Pulmonx Corp demands reviewing these metrics collectively while recognizing certain factors exert disproportionate influence.
Earnings Share
(1.41)
Revenue Per Share
2.279
Quarterly Revenue Growth
0.055
Return On Assets
(0.23)
Return On Equity
(0.74)
Understanding Pulmonx Corp requires distinguishing between market price and book value, where the latter reflects Pulmonx's accounting equity. The concept of intrinsic value—what Pulmonx Corp's is actually worth based on fundamentals—guides informed investors toward better entry and exit points. Market participants employ diverse analytical approaches to determine fair value and identify buying opportunities when prices dip below calculated worth. Market sentiment, economic cycles, and investor behavior can push Pulmonx Corp's price substantially above or below its fundamental value.
Understanding that Pulmonx Corp's value differs from its trading price is crucial, as each reflects different aspects of the company. Evaluating whether Pulmonx Corp represents a sound investment requires analyzing earnings trends, revenue growth, technical signals, industry dynamics, and expert forecasts. In contrast, Pulmonx Corp's trading price reflects the actual exchange value where willing buyers and sellers reach mutual agreement.